O
Optina Diagnostics
Technology for the early detection of disease through the eye
About Optina Diagnostics
Optina Diagnostics is pioneering the development of a groundbreaking tool designed to identify beta amyloid AB plaques, which are crucial biomarkers for Alzheimer's disease. The company operates in the healthcare diagnostics market, focusing on early detection of neurodegenerative diseases through non-invasive eye scans. Optina Diagnostics primarily serves healthcare providers, research institutions, and clinical study organizations. The business model revolves around selling and licensing its diagnostic technology to these clients, generating revenue through product sales, service agreements, and collaborative research projects. By leveraging advanced imaging techniques and artificial intelligence, Optina Diagnostics aims to revolutionize the early diagnosis of Alzheimer's, potentially altering the course of treatment and management for millions of patients worldwide. The company is also actively involved in community patient access programs to broaden the reach of its diagnostic solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Montreal, Canada
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 29.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Biotech and Pharma, Techbio, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $2.1M | $124M | Desjardins Capital · DigitalDx Ventures · Boehringer Ingelheim Venture Fund · Zoic Capital | ↗ |
| SERIES A✓Equity / VC | Oct 2021 | $25M | $99M | Boehringer Ingelheim Venture Fund · Desjardins Capital · DigitalDx Ventures · Advisors.Fund | ↗ |
Growth signals
Latest recorded traffic for Optina Diagnostics is 1.3K monthly website visits, up 381.5% over the last three months. Optina Diagnostics's team declined 8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
Zoic Capital
Pallasite Ventures
Desjardins Capital
Advisors.Fund
MEDTEQ+
Innovacorp
Anges Quebec
Real Ventures
Series A5 investors entered at this stage
DigitalDx Ventures
Boehringer Ingelheim Venture Fund
Hike Ventures- MEDTEQ
- BPBiomed Propulsion
Other known investors3 additional known investors
Barney Pell
Creative Destruction Lab
KGAP+
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Optina Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Optina Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.